Chronic inflammatory demyelinating polyneuropathy
(Redirected from Multifocal acquired demyelinating sensory and motor neuropathy)
A neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms
Chronic inflammatory demyelinating polyneuropathy | |
---|---|
![]() | |
Synonyms | CIDP |
Pronounce | |
Field | Neurology |
Symptoms | Progressive muscle weakness, numbness, tingling, fatigue, loss of reflexes, difficulty walking |
Complications | Permanent nerve damage, muscle atrophy, mobility impairment |
Onset | Gradual, often over weeks or months |
Duration | Chronic; may be relapsing-remitting or progressive |
Types | Typical CIDP, multifocal CIDP (Lewis-Sumner syndrome), pure motor or pure sensory CIDP |
Causes | Autoimmune attack on the myelin sheath of peripheral nerves |
Risks | Associated with other autoimmune diseases; may occur post-infection or post-vaccination |
Diagnosis | Nerve conduction studies, electromyography, lumbar puncture, nerve biopsy |
Differential diagnosis | Guillain–Barré syndrome, multiple sclerosis, diabetic neuropathy, Charcot–Marie–Tooth disease |
Prevention | None known |
Treatment | Corticosteroids, intravenous immunoglobulin (IVIG), plasma exchange, immunosuppressive therapy |
Medication | Prednisone, IVIG, azathioprine, rituximab |
Prognosis | Varies; many improve with treatment, some may have long-term disability |
Frequency | Estimated 1–8 per 100,000 people |
Deaths | Rare; usually due to complications rather than the disease itself |
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. It is considered an autoimmune disorder, where the body's immune system mistakenly attacks the myelin sheath, the protective covering of the nerves. CIDP is related to Guillain-Barré syndrome, but it progresses more slowly and lasts longer.
Pathophysiology[edit | edit source]
CIDP is caused by inflammation of the peripheral nerves and nerve roots, leading to the destruction of the myelin sheath. This demyelination disrupts the normal conduction of electrical impulses along the nerves, resulting in muscle weakness, sensory disturbances, and loss of reflexes. The exact cause of the autoimmune response in CIDP is not fully understood, but it is believed to involve both cellular and humoral immune mechanisms.
Symptoms[edit | edit source]
The symptoms of CIDP can vary widely among individuals, but they typically include:
- Progressive muscle weakness, particularly in the arms and legs
- Tingling or numbness in the extremities
- Loss of deep tendon reflexes
- Fatigue
- Difficulty walking
- Sensory ataxia
The progression of symptoms can be gradual, occurring over several months, and may fluctuate in severity.
Diagnosis[edit | edit source]
Diagnosing CIDP involves a combination of clinical evaluation, laboratory tests, and electrophysiological studies. Key diagnostic criteria include:
- Clinical presentation of progressive weakness and sensory dysfunction
- Electromyography (EMG) and nerve conduction studies showing demyelination
- Elevated protein levels in the cerebrospinal fluid (CSF) without a significant increase in white blood cells
A nerve biopsy may be performed in some cases to confirm the diagnosis by demonstrating demyelination and inflammation.
Treatment[edit | edit source]
The primary goal of treatment for CIDP is to reduce inflammation and suppress the immune response. Common treatment options include:
- Corticosteroids such as prednisone
- Intravenous immunoglobulin (IVIG)
- Plasmapheresis (plasma exchange)
- Immunosuppressive drugs such as azathioprine or rituximab
Physical therapy and occupational therapy are also important components of managing CIDP, helping to maintain muscle strength and improve functional abilities.
Prognosis[edit | edit source]
The prognosis for individuals with CIDP varies. Some patients experience significant improvement with treatment, while others may have a more chronic course with relapses and remissions. Early diagnosis and treatment are crucial for improving outcomes and preventing long-term disability.
Related pages[edit | edit source]
External links[edit | edit source]
Classification | |
---|---|
External resources |
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD